Date:8/17/2010

t, net 165,120 181,931 26,828 Lease prepayments 8,541 8,364 1,233 Non-current deposits 10,067 8,112 1,196 Intangible assets, net 4,125 3,575 527 Long term receivable -- 3,352 494 Deferred tax assets 1,567 2,516 371 Total assets 1,053,461 1,124,791 165,862 Liabilities Current liabilities Accounts payable 2,736 3,080 454 Deferred grant income 374 374 55 Accrued expenses and other payables 33,421 38,198 5,633 Income tax payable 1,914 4,117 607 Total current liabilities 38,445 45,769 6,749 Deferred grant income 2,778 2,590 382 Total liabilities 41,223 48,359 7,131 Commitments and contingencies -- -- -- Shareholders' equity Share capital -ordinary shares US$0.0001 par value, 500,000,000 shares authorized, 150,641,461 and 151,053,710 issued and outstanding as of December 31, 2009 and June 30, 2010, respectively 121 121 18 Additional paid-in capital 915,267 929,144 137,012 Accumulated other comprehensive loss (100,608) (102,466) (15,110) Retained earnings 197,458 249,633 36,811 Total shareholders' equity 1,012,238 1,076,432 158,731 Total liabilities and shareholders' equity 1,053,461 1,124,791 165,862 3SBio Inc. Unaudited quarterly consolidated statements of income (expressed in thousands, except per share , per ADS and other share and ADS data) For the Three For the Three Months Ended Months Ended June 30, 2009 June 30, 2010 RMB US$ RMB US$ (unaudited) (unaudited) (unaudited) (unaudited) Net Revenues: EPIAO 51,081 7,479 62,797 9,260 TPIAO 22,217 3,253 32,135 4,739 Intefen 1,289 189 1,236 182 Inleusin 425 62 500 74 Iron sulcrose 2,951 432 4,459 658 Export 3,520 515 2,926 431 Others -- -- 1,439 212 Total net revenues 81,483 11,930 105,492 15,556 Cost of revenues (6,518) (954) (10,734) (1,583) Gross profit 74,965 10,976 94,758 13,973 Operating expenses Research and development costs (4,252) (623) (5,741) (847) Sales, marketing and distribution expenses (36,242) (5,306) (47,585) (7,017) General and administrative expenses (8,662) (1,268) (13,516) (1,993) Total operating expen
'/>"/>

SOURCE 3SBio Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Related biology technology :

1. 3SBio Inc. Announces Second Quarter 2008 Results
2. 3SBio Inc. to Hold Annual General Meeting
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. 3SBio Inc. Announces Results of Annual General Meeting
5. 3SBio Inc. to Present at the UBS Global Life Sciences Conference
6. 3SBio Inc. Files for SFDA Approval of High-dose (36,000 IU) EPIAO
7. 3SBio Inc. Schedules 2008 Third Quarter Earnings Release on Monday, November 10, 2008
8. 3SBio Inc. Announces Preliminary Third Quarter 2008 Results
9. 3SBio Inc. Files for SFDA Approval of NuLeusin
10. 3SBio Inc. Announces Third Quarter 2008 Results
11. 3SBio Inc. to Present at the Piper Jaffray 20th Annual Health Care Conference